The clinically studied Wegovy maintenance dose is the therapeutic dose at which the patient reached their weight loss goal typically 1.7 mg or 2.4 mg weekly, and now up to 7.2 mg weekly under the Wegovy HD approval
Eli Lillys recent approval for Zepbound, a GLP-1/GIP receptor agonist known as Mounjaro in the diabetes market, sets the stage for a fierce battle with Novo for market dominance
If you have any questions about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy
The jurys still out, but some research suggests its a good supplement for folks with neurodegenerative diseases like Alzheimers disease or Parkinsons disease
This information highlights that these higher targets are more than just theoretical optimization
What the plateau does raise is the question of what happens next, and this is where an honest conversation matters